Survival benefit associated with screening of patients at elevated risk for pancreatic cancer
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von William J Kane und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Early Detection of Cancer, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background & Objectives Screening for pancreatic cancer is recommended for individuals with a strong family history, certain genetic syndromes, or a neoplastic cyst of the pancreas. However, limited data supports a survival benefit attributable to screening these higher‐risk individuals.
Methods
All patients enrolled in screening at a High‐Risk Pancreatic Cancer Clinic (HRC) from July 2013 to June 2020 were identified from a prospectively maintained institutional database and compared to patients evaluated at a Surgical Oncology Clinic (SOC) at the same institution during the same period. Clinical outcomes of patients selected for surgical resection, particularly clinicopathologic stage and overall survival, were compared.
Results
Among 826 HRC patients followed for a median (IQR) of 2.3 (0.8–4.2) years, 128 were selected for surgical resection and compared to 402 SOC patients selected for resection. Overall survival was significantly longer among HRC patients (median survival: not reached vs. 2.6 years, p < 0.001). Among 31 HRC and 217 SOC patients with a diagnosis of pancreatic ductal adenocarcinoma (PDAC), the majority of HRC patients were diagnosed with stage 0 disease (carcinoma in situ), while the majority of SOC patients were diagnosed with stage II disease ( p < 0.001). Overall survival after resection of invasive PDAC was also significantly longer among HRC patients compared to SOC patients (median survival 5.5 vs. 1.6 years, p = 0.002).
Conclusion
Patients at increased risk for PDAC and followed with guideline‐based screening exhibited downstaging of disease and improved survival from PDAC in comparison to patients who were not screened.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
- Department of Medicine, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia, USA.
- School of Medicine, University of Virginia, Charlottesville, University of Virginia, USA.
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Kane, W. J., Haden, K. R., Martin, E. N., Shami, V. M., Wang, A. Y., Strand, D. S., Adair, S. J., Nagdas, S., Tsung, A., Zaydfudim, V. M., Adams, R. B., & Bauer, T. W. (2024). Survival benefit associated with screening of patients at elevated risk for pancreatic cancer. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27784
Vancouver
Kane WJ, Haden KR, Martin EN, Shami VM, Wang AY, Strand DS, et al. Survival benefit associated with screening of patients at elevated risk for pancreatic cancer. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27784
BibTeX
@article{Kane2024,
author = {Kane, William J and Haden, Kathleen R and Martin, Elizabeth N and Shami, Vanessa M and Wang, Andrew Y and Strand, Daniel S and Adair, Sara J and Nagdas, Sarbajeet and Tsung, Allan and Zaydfudim, Victor M and Adams, Reid B and Bauer, Todd W},
title = {Survival benefit associated with screening of patients at elevated risk for pancreatic cancer},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27784}
}
EUVIMED